Short answer
Aurinia Pharmaceuticals Inc. (AUPH) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $83M (up 18.9% year over year) with net income of $37M.
Q2 2026 key financials · XBRL
- Revenue
- $83M
- +18.9% YoY · +7.1% QoQ
- Net income
- $37M
- +73.9% YoY · +8.9% QoQ
- Operating margin
- 55.7%
- EPS (diluted)
- $0.28
- +75.0% YoY · +12.0% QoQ
Source: XBRL data from the Aurinia Pharmaceuticals Inc. (AUPH) Q2 2026 10-Q on SEC EDGAR. USD.
Aurinia Pharmaceuticals Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Quarterly revenue $83.2M, up 19% YoY from $70.0M
- Gross margin 92% vs 90% YoY
- LUPKYNIS net product sales $79.4M, up 19% YoY from $66.6M
- Operating income $46.3M vs $20.1M YoY; net income $37.4M vs $21.5M
- Cash and investments $443.1M vs $398.0M; operating cash flow $85.1M, up 87% YoY; $74.9M share repurchases
- 2026 SG&A expected substantially consistent with 2025; R&D expense expected to increase with development activities
Risk Factors
- No risk-factors section provided; supplied text covers share repurchases and exhibits
- Share repurchase authorization increased by $150 million in July 2025
- Repurchases totaled 23.3 million shares for $213.4 million
- Remaining repurchase capacity $86.634 million as of June 30, 2026
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Aurinia Pharmaceuticals Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.